Abstract
Arachidonic acid (AA) metabolites are lipid signalling mediators that play a central role in a broad array of physiological and pathophysiological processes, including cell proliferation and differentiation. AA metabolism diverges into two main pathways, the cyclooxygenase (COX) pathway, which leads to prostaglandin and thromboxane production, and the lipoxygenase (LOX) pathway, which leads to the leukotriene and hydroxyeicosatetraenoic acid production. These inflammatory molecules exert profound biological effects that enhance the development and progression of human cancers. A large number of synthetic drugs and natural molecules inhibit the enzymes involved in these pathways and thus prevent, delay or reverse inflammation. They may also prove useful in the chemoprevention of cancer. These studies have primarily used non-steroidal anti-inflammatory drugs, which block the COX pathway. Recent pre-clinical studies indicate that the LOX pathway is also a key target for cancer prevention strategy. This article reviews the role of COX and LOX inhibitors in cell proliferation and cancer.
Keywords: prostaglandins, leukotrienes, eicosanoids, cyclooxygenase, lipoxygenase, cell proliferation, cell growth, neoplasia
Current Enzyme Inhibition
Title: Arachidonic Acid Cascade Enzyme Inhibition and Cancer
Volume: 1 Issue: 2
Author(s): J. J. Moreno
Affiliation:
Keywords: prostaglandins, leukotrienes, eicosanoids, cyclooxygenase, lipoxygenase, cell proliferation, cell growth, neoplasia
Abstract: Arachidonic acid (AA) metabolites are lipid signalling mediators that play a central role in a broad array of physiological and pathophysiological processes, including cell proliferation and differentiation. AA metabolism diverges into two main pathways, the cyclooxygenase (COX) pathway, which leads to prostaglandin and thromboxane production, and the lipoxygenase (LOX) pathway, which leads to the leukotriene and hydroxyeicosatetraenoic acid production. These inflammatory molecules exert profound biological effects that enhance the development and progression of human cancers. A large number of synthetic drugs and natural molecules inhibit the enzymes involved in these pathways and thus prevent, delay or reverse inflammation. They may also prove useful in the chemoprevention of cancer. These studies have primarily used non-steroidal anti-inflammatory drugs, which block the COX pathway. Recent pre-clinical studies indicate that the LOX pathway is also a key target for cancer prevention strategy. This article reviews the role of COX and LOX inhibitors in cell proliferation and cancer.
Export Options
About this article
Cite this article as:
Moreno J. J., Arachidonic Acid Cascade Enzyme Inhibition and Cancer, Current Enzyme Inhibition 2005; 1 (2) . https://dx.doi.org/10.2174/1573408054022261
DOI https://dx.doi.org/10.2174/1573408054022261 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recognition of Nucleic Acids by Toll-Like Receptors and Development of Immunomodulatory Drugs
Current Medicinal Chemistry p-tert-Butylcalix[8]arene: An Effective Nano-ranged Organocatalyst for the Syntheses of Xanthenes and Acridines
Current Organocatalysis Endocrine Therapy Resistance: Current Status, Possible Mechanisms and Overcoming Strategies
Anti-Cancer Agents in Medicinal Chemistry Synthesis and Antiviral Activity of 2-aryl-4H-chromen-4-one Derivatives Against Chikungunya Virus
Letters in Drug Design & Discovery Regulation of G-Protein-Coupled Receptor Signalling by the Scaffolding Proteins Spinophilin/Neurabin 2 and Neurabin 1
Current Chemical Biology General Aspects of Metal Toxicity
Current Medicinal Chemistry Are Chemically Reactive Metabolites Responsible for Adverse Reactions to Drugs?
Current Drug Metabolism Luteolin, a Flavonoid with Potential for Cancer Prevention and Therapy
Current Cancer Drug Targets MicroRNAs in Diabetic β Cell Dysfunction and their Role as Biomarkers
Current Signal Transduction Therapy Recent Approaches to Improve the Antitumor Efficacy of Temozolomide
Current Medicinal Chemistry Absorption, Disposition and Pharmacokinetics of Solid Lipid Nanoparticles
Current Drug Metabolism Cholesterol Lowering Therapy: Treat to Target or Reduce the Global Risk? The Unresolved Problem of Residual Risk
Current Pharmaceutical Design Design, Synthesis and Pharmacological Evaluation of Gastro- Protective Anti-inflammatory Analgesic Agents based on Dual Oxidative Stress / Cyclooxygenase Inhibition
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Proteases and Their Role in Chronic Inflammatory Lung Diseases
Current Drug Targets Obstructive Sleep Apnea and Autoimmune Rheumatic Disease: Is there Any Link?
Inflammation & Allergy - Drug Targets (Discontinued) Recent Advances in PUVA Photochemotherapy and PDT for the Treatment of Cancer
Current Pharmaceutical Design Complement and Complement Regulatory Proteins as Potential Molecular Targets for Vascular Diseases
Current Pharmaceutical Design NADPH Oxidases and Inflammatory Bowel Disease
Current Medicinal Chemistry Factors Influencing Body Mass Index, Appetite Control, and the Role of Glutamate and Excess Nutritional Protein During Child Development: A Review
Current Pediatric Reviews Recent Advances in Discovering the Role of CCL5 in Metastatic Breast Cancer
Mini-Reviews in Medicinal Chemistry